Why do IDE annual reports frequently generate Form 483 findings during BIMO inspections?

Inspectors evaluate whether the annual report content matches the sponsor's actual internal records on enrollment, deviations, and adverse events, and gaps between what was reported and what the underlying data shows are a leading source of findings. Late submission, incomplete deviation summaries, or a failure to reconcile site-level adverse event logs with the aggregated sponsor report are the most common specific problems inspectors cite.

How can sponsors use the annual report process for more than just compliance?

Because the annual report requires aggregating enrollment trends, deviation patterns, and adverse event rates across all participating sites, preparing it is a natural opportunity for portfolio-level oversight that can surface site conduct issues, protocol design problems, or emerging safety signals before they become larger problems. Sponsors who treat the report purely as a compliance checkbox miss this built-in opportunity for proactive study governance.

Is the IDE annual report the same as the MDR reporting sponsors do for approved devices?

No, the IDE annual progress report under 21 CFR 812.150(b)(5) is specific to ongoing investigational device studies conducted under an approved IDE and is submitted through the IDE supplement framework. Medical Device Reporting (MDR) under 21 CFR Part 803 is a separate post-market adverse event reporting obligation that applies to marketed devices, using a different form and timeline; sponsors running both an active IDE study and a marketed predicate device need to track each obligation separately.

Back to Clinical Trials & Evidence

Clinical & TrialsClinical Evidence Post-Market & Safety Global Markets

IDE Annual Progress Report

Annual report sponsors must submit to FDA summarizing the progress of an approved IDE study, including enrollment, deviations, and adverse events.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed June 20, 2026

Definition

Under 21 CFR 812.150(b)(5), IDE sponsors must submit a Progress Report to FDA at least yearly, summarizing the conduct of the investigation. Required content includes enrollment status (subjects enrolled, completed, withdrawn), summary of adverse events and UADEs, deviations from the investigational plan, sponsor monitoring activities, IRB activity (approvals, suspensions, terminations), and any other information relevant to the rights, safety, or welfare of subjects. Reports are due to FDA on the anniversary of the IDE approval and to reviewing IRBs at the frequency the IRB requires.

What the regulation says

21 CFR 812.150(b)(5) defines content and timing. FDA's BIMO Compliance Program 7348.811 (Sponsors, Contract Research Organizations, and Monitors) is the inspection reference.

What this means in practice

IDE annual reports are routinely reviewed by FDA bioresearch monitoring (BIMO) inspectors and are a leading source of Form 483 findings when content is incomplete or late. Sponsors should treat annual report preparation as an opportunity for portfolio-level oversight: cross-site enrollment trends, deviation patterns, and AE rates often reveal study conduct issues that warrant intervention before the next report.

Examples

A sponsor preparing their IDE annual progress report noticed a higher than expected rate of a particular adverse event at one investigational site, prompting an internal audit and retraining.
During an FDA BIMO inspection, the investigator reviewed a recent IDE annual progress report and cited the sponsor for not adequately summarizing all reported Unanticipated Adverse Device Effects.
The clinical team compiled data on subject enrollment, protocol deviations, and IRB approvals from multiple sites to fulfill the requirements of their annual IDE progress report submission.

Common pitfalls

•Missing the annual deadline, reports are due on the anniversary of IDE approval, not the calendar year.
•Reporting only aggregate counts without trend analysis, sponsors are expected to interpret, not just summarize.
•Treating the annual report as administrative, it is a sponsor compliance artifact reviewed by FDA inspectors.

Frequently asked questions

The report must summarize enrollment status (subjects enrolled, completed, and withdrawn), adverse events and UADEs observed during the reporting period, any deviations from the investigational plan, the sponsor's monitoring activities, relevant IRB actions such as approvals, suspensions, or terminations, and any other information bearing on the rights, safety, or welfare of subjects. It is due to FDA at least yearly, on the anniversary of IDE approval, and to reviewing IRBs at whatever frequency each IRB requires.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Clinical & Trials

IDE Supplement

Amendment to an approved Investigational Device Exemption for protocol or device changes.

Clinical & Trials

Investigational Device Exemption(IDE)

FDA authorization to use an investigational device in a clinical study.

Clinical & Trials

Investigator Brochure(IB)

Compilation of clinical and nonclinical information on an investigational device given to clinical investigators, establishes what's 'anticipated' for UADE determinations.

Clinical & Trials

Protocol Deviation

Departure from the approved clinical investigation plan.

Clinical Trials & Evidence

· From this learning path

Clinical & Trials

Institutional Review Board(IRB)

Board that reviews and approves human-subjects research at an institution.

Adjacent lesson

Clinical & Trials

Adaptive Trial Design

Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data.

Clinical & Trials

Adverse Event(AE)

Any untoward medical occurrence in a subject, whether or not related to the device.

Clinical & Trials

Clinical Evaluation Report(CER)

Documented assessment of clinical data demonstrating EU MDR conformity for a device.

Cited by

Where this term appears across MedTech Terms.

Learning paths (1)

Clinical Trials & EvidenceLesson 3 of 18

Ecosystems (3)

Latest in MedTech

Sources

3 sources

Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 1Binding law and standards· 1Tier 2Regulator guidance and consensus· 2

Link health: 3 verified· last checked 2026-06-20

eCFR·1FDA·2

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Clinical & Trials0 / 52

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Clinical & Trials
Sources: 3
Updated: 6/20/2026

Compare with another term

Learn in 60 seconds

Annual report sponsors must submit to FDA summarizing the progress of an approved IDE study, including enrollment, deviations, and adverse events.

·IDE annual reports are routinely reviewed by FDA bioresearch monitoring (BIMO) inspectors and are a leading source of Form 483 findings when content is incomplete or late.
·Reports are due to FDA on the anniversary of the IDE approval and to reviewing IRBs at the frequency the IRB requires.

Remember this

Watch out: Missing the annual deadline, reports are due on the anniversary of IDE approval, not the calendar year.

Related terms

You may also need

Auto-suggested from Clinical & Trials and shared keywords.

All Clinical & Trials terms

From the Blue Goat network

Related resources and services on this topic.

MedTech Launchpad
MedTech funding rounds, accelerators, and launch resources.